Edwards Lifesciences (EW) Tops Q4 EPS by 1c; Guides Above the Street

Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Revenue for the quarter came in at $671.1 million versus the consensus estimate of $648.74 million.

GUIDANCE:

Edwards Lifesciences sees FY2016 EPS of $2.57-$2.67, versus the consensus of $2.40.

"We are very pleased to report strong fourth quarter results, which exceeded our expectations and contributed to another successful year, both in financial performance and progress on important new therapies," said Michael A. Mussallem, chairman and CEO. "These positive results were due to continued demand for transcatheter aortic valve replacement therapy, and the strong performance of all product lines this quarter. We were also pleased to receive FDA approval for our PARTNER 3 Trial to study patients determined to be at low surgical risk, which may eventually enable heart teams to offer a choice of therapies to a broader group of patients."

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Plexus Corp (PLXS) Tops Q2 EPS by 7c
• Amerant Bancorp Inc. (AMTB) Misses Q1 EPS by 5c